Literature DB >> 22136176

The mechanisms of antihyperalgesic effect of topiramate in a rat model of inflammatory hyperalgesia.

Sonja Lj Paranos1, Maja A Tomić, Ana M Micov, Radica M Stepanović-Petrović.   

Abstract

Recent studies have shown that topiramate, a structurally novel anticonvulsant, exerts antinociceptive activity in animal models of neuropathic, acute somatic, and visceral pain. This study was aimed to examine: (i) the effects of systemically and locally peripherally administered topiramate in the rat inflammatory pain model and (ii) the potential role and site(s) of gamma-aminobutyric acid (GABA), opioid, and adrenergic receptors in topiramate's antihyperalgesia. Rats received intraplantar (i.pl.) injections of the pro-inflammatory compound carrageenan. A paw pressure test was used to determine: (i) the effect of systemic and local peripheral topiramate on carrageenan-induced hyperalgesia and (ii) the effects of systemic and local peripheral bicuculline (selective GABAA receptor antagonist), naloxone (nonselective opioid receptor antagonist), and yohimbine (selective α2-adrenergic receptor antagonist) on topiramate-induced antihyperalgesia. Systemic topiramate (40-160 mg/kg; p.o.) produced a significant dose-dependent reduction in the paw inflammatory hyperalgesia induced by carrageenan. The antihyperalgesic effect of systemic topiramate was significantly decreased by systemic bicuculline (0.5-1 mg/kg; i.p.), naloxone (2-5 mg/kg; i.p.), and yohimbine (1-3 mg/kg; i.p.). Local peripheral topiramate (0.03-0.34 mg/paw; i.pl.) also produced significant dose-dependent antihyperalgesia, which was significantly depressed by local peripheral yohimbine (0.05-0.2 mg/paw; i.pl.) but not by local peripheral bicuculline (0.15 mg/paw; i.pl.) or naloxone (0.1 mg/paw; i.pl.). The results suggest that topiramate produces systemic and local peripheral antihyperalgesia in an inflammatory pain model, which is, at least partially, mediated by central GABAA and opioid receptors and by peripheral and most probably central α2-adrenergic receptors. These findings contribute to better understanding of topiramate's action in pain states involving inflammation.
© 2011 The Authors Fundamental and Clinical Pharmacology © 2011 Société Française de Pharmacologie et de Thérapeutique. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22136176     DOI: 10.1111/j.1472-8206.2011.01018.x

Source DB:  PubMed          Journal:  Fundam Clin Pharmacol        ISSN: 0767-3981            Impact factor:   2.748


  5 in total

1.  Nociceptive blink reflex habituation biofeedback in migraine.

Authors:  M de Tommaso; M Delussi
Journal:  Funct Neurol       Date:  2017 Jul/Sep

Review 2.  Do antiepileptic drugs increase the risk of infectious diseases? A meta-analysis of placebo-controlled studies.

Authors:  Gaetano Zaccara; Fabio Giovannelli; Filippo Sean Giorgi; Valentina Franco; Sara Gasparini; Francesco Mandò Tacconi
Journal:  Br J Clin Pharmacol       Date:  2017-05-07       Impact factor: 4.335

3.  Hypnic Headache Responds to Topiramate: A Case Report and a Review of Mechanisms of Action of Therapeutic Agents.

Authors:  Hassan Kesserwani
Journal:  Cureus       Date:  2021-03-09

4.  Topiramate via NMDA, AMPA/kainate, GABAA and Alpha2 receptors and by modulation of CREB/BDNF and Akt/GSK3 signaling pathway exerts neuroprotective effects against methylphenidate-induced neurotoxicity in rats.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Sulail Fatima; Tabassom Beiranvand; Shiva Mozaffari
Journal:  J Neural Transm (Vienna)       Date:  2017-08-09       Impact factor: 3.575

5.  Effects of topiramate on dysaesthetic pain in a patient with multiple sclerosis.

Authors:  Antonio Siniscalchi; Luca Gallelli; Giovambattista De Sarro
Journal:  Clin Drug Investig       Date:  2013-02       Impact factor: 2.859

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.